Cite
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.
MLA
Martino, Massimo, et al. “Effectiveness of Biosimilar Pegfilgrastim in Patients with Multiple Myeloma after High-Dose Melphalan and Autologous Stem Cell Transplantation.” Annals of Hematology, vol. 102, no. 7, July 2023, pp. 1915–25. EBSCOhost, https://doi.org/10.1007/s00277-023-05228-z.
APA
Martino, M., Gori, M., Porto, G., Pellicano, M., Santoro, L., Verduci, C., Canale, F. A., Loteta, B., Moscato, T., Alati, C., Ieracitano, M. C., Cuzzocrea, A., Altomonte, M., Florenzano, M. T., Morabito, A., Irrera, G., Naso, V., Pugliese, M., Console, G., & Ferreri, A. (2023). Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. Annals of Hematology, 102(7), 1915–1925. https://doi.org/10.1007/s00277-023-05228-z
Chicago
Martino, Massimo, Mercedes Gori, Gaetana Porto, Maria Pellicano, Ludovica Santoro, Chiara Verduci, Filippo Antonio Canale, et al. 2023. “Effectiveness of Biosimilar Pegfilgrastim in Patients with Multiple Myeloma after High-Dose Melphalan and Autologous Stem Cell Transplantation.” Annals of Hematology 102 (7): 1915–25. doi:10.1007/s00277-023-05228-z.